Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cross

Showing results (521-530 of 595) with videos related to

Pageof 60
Sort By:
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Blood|August 21, 2013
Comprehensive mutational profiling in advanced systemic mastocytosisJuliana Schwaab, Susanne Schnittger, Karl Sotlar, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|February 24, 2020
Revisiting the bacterial mutagenicity assays: Report by a workgroup of the International Workshops on Genotoxicity Testing (IWGT)Rita Schoeny, Kevin P Cross, David M DeMarini, et al.
Blood|April 2, 2014
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinibChan Y Cheah, Kate Burbury, Jane F Apperley, et al.
International Journal of Molecular Sciences|April 3, 2021
Adverse Prognostic Impact of the <i>KIT</i> D816V Transcriptional Activity in Advanced Systemic MastocytosisNicole Naumann, Johannes Lübke, Sofie Baumann, et al.
International Journal of Pediatric Otorhinolaryngology|May 10, 2017
Effect of gentamicin and levels of ambient sound on hearing screening outcomes in the neonatal intensive care unit: A pilot studyAngela C Garinis, Selena Liao, Campbell P Cross, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysisFrancis J Giles, Delphine Rea, Gianantonio Rosti, et al.
British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.
Blood|October 28, 2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideClaire N Harrison, Adam J Mead, Anesh Panchal, et al.
Leukemia|February 6, 2015
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemiaN C P Cross, H E White, D Colomer, et al.
Pageof 60

Showing results (521-530 of 595) with videos related to

Sort By:
Pageof 60
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Blood|August 21, 2013
Comprehensive mutational profiling in advanced systemic mastocytosisJuliana Schwaab, Susanne Schnittger, Karl Sotlar, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|February 24, 2020
Revisiting the bacterial mutagenicity assays: Report by a workgroup of the International Workshops on Genotoxicity Testing (IWGT)Rita Schoeny, Kevin P Cross, David M DeMarini, et al.
Blood|April 2, 2014
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinibChan Y Cheah, Kate Burbury, Jane F Apperley, et al.
International Journal of Molecular Sciences|April 3, 2021
Adverse Prognostic Impact of the <i>KIT</i> D816V Transcriptional Activity in Advanced Systemic MastocytosisNicole Naumann, Johannes Lübke, Sofie Baumann, et al.
International Journal of Pediatric Otorhinolaryngology|May 10, 2017
Effect of gentamicin and levels of ambient sound on hearing screening outcomes in the neonatal intensive care unit: A pilot studyAngela C Garinis, Selena Liao, Campbell P Cross, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysisFrancis J Giles, Delphine Rea, Gianantonio Rosti, et al.
British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.
Blood|October 28, 2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideClaire N Harrison, Adam J Mead, Anesh Panchal, et al.
Leukemia|February 6, 2015
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemiaN C P Cross, H E White, D Colomer, et al.
Pageof 60